Other antibodies in clinical trials.
| Antibody . | Characteristics . | Target . | Cells . | Diseases . |
|---|---|---|---|---|
| Campath-1H | Humanized rat Mab | CD52 | All mononuclear cells | CLL, PLL, NHL |
| HLL2 (epratuzumab) | Humanized murine Mab, also radiolabelled | CD22 | Mature B cells | B-NHL |
| Hu1D10 | Humanized murine IgG1 Mab | HLA-DR β chain | B cells, macrophages, dendritic cells | B-NHL |
| HuM291 | Humanized murine Mab | CD3 | Mature T cells | Psoriasis, Renal transplant, T-NHL |
| Gemtuzumab (Mylotarg) | Humanized murine Mab-drug (calicheamycin conjugate) | CD33 | Myeloid cells | AML |
| 131I-tositumomab (Bexxar) | Murine Mab radiolabelled with 131I | CD20 | Mature B cells | B-NHL, |
| IDEC-Y2B8 (Zevalin) | Murine Mab radio-labelled with 90Y | CD20 | Mature B cells | B-NHL |
| Lym-1 | Murine Mab radio-labelled with 131I or 67Cu | HLA-D | B cells, macrophages, dendritic cells | B-NHL |
| Abbreviations: Mab, monoclonal antibody; CLL, chronic lymphocytic leukemia; PLL, prolymphocytic leukemia; NHL, non-Hodgkin's lymphoma, AML, acute myeloid leukemia | ||||
| Antibody . | Characteristics . | Target . | Cells . | Diseases . |
|---|---|---|---|---|
| Campath-1H | Humanized rat Mab | CD52 | All mononuclear cells | CLL, PLL, NHL |
| HLL2 (epratuzumab) | Humanized murine Mab, also radiolabelled | CD22 | Mature B cells | B-NHL |
| Hu1D10 | Humanized murine IgG1 Mab | HLA-DR β chain | B cells, macrophages, dendritic cells | B-NHL |
| HuM291 | Humanized murine Mab | CD3 | Mature T cells | Psoriasis, Renal transplant, T-NHL |
| Gemtuzumab (Mylotarg) | Humanized murine Mab-drug (calicheamycin conjugate) | CD33 | Myeloid cells | AML |
| 131I-tositumomab (Bexxar) | Murine Mab radiolabelled with 131I | CD20 | Mature B cells | B-NHL, |
| IDEC-Y2B8 (Zevalin) | Murine Mab radio-labelled with 90Y | CD20 | Mature B cells | B-NHL |
| Lym-1 | Murine Mab radio-labelled with 131I or 67Cu | HLA-D | B cells, macrophages, dendritic cells | B-NHL |
| Abbreviations: Mab, monoclonal antibody; CLL, chronic lymphocytic leukemia; PLL, prolymphocytic leukemia; NHL, non-Hodgkin's lymphoma, AML, acute myeloid leukemia | ||||